Actively Recruiting
Oral Cannabidiol Tablets to Reduce Pain and Improve Function in Adults with Knee Osteoarthritis Aged 40 to 75
Led by NYU Langone Health · Updated on 2026-06-09
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating if cannabidiol CBD orally dissolving tablets can reduce pain, improve function, and increase patient satisfaction in people with knee osteoarthritis. CBD is a non-psychoactive compound from the cannabis plant that is being studied for its potential to help with pain and inflammation. This study is a multi-center, randomized, placebo-controlled trial comparing CBD tablets to placebo in patients undergoing physiotherapy and home exercises. Participants will be randomly assigned to one of two groups. The first group will take 50 mg of CBD orally dissolving tablets three times daily total 150 mg per day for up to 84 days. The second group will take placebo tablets with the same schedule. Both groups will continue physiotherapy and home exercise programs during the study. Participants will rate their pain using the Visual Analog Scale VAS at multiple points during the study Days 1, 2, 7, 14, 28, 42, and 84. Patient satisfaction with pain management and clinical outcomes will also be measured over time using the Knee Injury and Osteoarthritis Outcome Score KOOS and VAS satisfaction scores. The study includes follow-up assessments up to 60 weeks to monitor outcomes and corticosteroid use.
CONDITIONS
Brief Title
Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis
Research Team
M
Michael J Alaia, MD
L
Layne Estes
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here